KURA
Price
$9.61
Change
-$0.25 (-2.54%)
Updated
Oct 23 closing price
Capitalization
854.91M
10 days until earnings call
Intraday BUY SELL Signals
MBX
Price
$48.50
Change
-$1.96 (-3.88%)
Updated
Oct 23 closing price
Capitalization
2.34B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KURA vs MBX

KURA vs MBX Comparison Chart in %
View a ticker or compare two or three
VS
KURA vs. MBX commentary
Oct 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Buy and MBX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for KURA with price predictions
Oct 23, 2026

KURA in downward trend: price dove below 50-day moving average on September 23, 2026

KURA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for KURA crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for KURA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KURA's RSI Indicator exited the oversold zone, 31 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 63 cases where KURA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

Following a +9.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 214 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. KURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.652) is normal, around the industry mean (3.043). P/E Ratio (-2.852) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MBX with price predictions
Oct 23, 2026

MBX's RSI Oscillator ascends from oversold territory

The RSI Indicator for MBX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 8 similar instances when the indicator left oversold territory. In 8 of the 8 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 23 of 27 cases where MBX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

Following a +2.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBX advanced for three days, in 120 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

MBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBX as a result. In 26 of 29 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for MBX turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In 14 of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

MBX moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for MBX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.703) is normal, around the industry mean (3.043). P/E Ratio (-20.464) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
KURA: Fundamental Ratings
KURA
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
28
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KURAMBX
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 3 days ago
90%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 24, 2026
Stock price -- (KURA: $9.61 vs. MBX: $48.50)
Brand notoriety: KURA and MBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 88% vs. MBX: 140%
Market capitalization -- KURA: $854.91M vs. MBX: $2.34B
KURA [@Biotechnology] is valued at $854.91M. MBX’s [@Biotechnology] market capitalization is $2.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 1 FA rating(s) are green while MBX’s FA Score has 1 green FA rating(s).

  • KURA’s FA Score: 1 green, 4 red.
  • MBX’s FA Score: 1 green, 4 red.
According to our system of comparison, MBX is a better buy in the long-term than KURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 4 TA indicator(s) are bullish while MBX’s TA Score has 4 bullish TA indicator(s).

  • KURA’s TA Score: 4 bullish, 4 bearish.
  • MBX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KURA is a better buy in the short-term than MBX.

Price Growth

KURA (@Biotechnology) experienced а +5.84% price change this week, while MBX (@Biotechnology) price change was -2.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.

Reported Earning Dates

KURA is expected to report earnings on Nov 03, 2026.

MBX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KURA
Daily Signal:
Gain/Loss:
MBX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

MBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBX has been loosely correlated with NAMS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MBX jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBX
1D Price
Change %
MBX100%
-3.88%
NAMS - MBX
40%
Loosely correlated
-8.67%
IMVT - MBX
39%
Loosely correlated
-2.37%
SYRE - MBX
38%
Loosely correlated
-2.17%
PVLA - MBX
38%
Loosely correlated
-1.02%
SVRA - MBX
38%
Loosely correlated
-7.05%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HOFT12.780.01
+0.08%
Hooker Furnishings Corp
PFIS70.68-0.25
-0.35%
Peoples Financial Services Corp
KEY21.08-0.13
-0.61%
KeyCorp
RMCF0.87-0.03
-3.46%
Rocky Mountain Chocolate Factory
AMLX27.20-1.37
-4.80%
Amylyx Pharmaceuticals